Clinical Trial Update: First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia [Phase 3]

View source ↗

Summary

A Phase 3 trial in Asia compared first-line gefitinib (IRESSA) with carboplatin/paclitaxel in non-small cell lung cancer, with results posted in May 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Iressa (gefitinib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: AstraZeneca | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2010-05-17